Kornimate/medical-research-clean huggingface dataset:
chidamide for advanced cephalic and cervical adenocystic carcinoma: evaluation of efficiency and safety

Conditions: Adenocystic Carcinoma

Summary: the purpose of this trial is to evaluate the efficiency and safety of chidamide in advanced cephalic and cervical adenoid cystic carcinoma. chidamide is given to patients with advanced cephalic and cervical adenoid cystic carcinoma with the dosage of 30mg,twice a week, then overall survival, event-free survival are accessed for efficiency, and laboratory tests about the function of vital organs are accessed for safety.


Eligibility criteria:
inclusion criteria: 1. patients of advanced cephalic and cervical adenocystic carcinoma with pathological and imaging evidences, with local relapse or metastasis or refractory towards treatment. 2. age 18-75, male or female, expected survival≥ 3 months. 3. ecog 0-2. 4. with at least one evaluable disease focus. 5. organ functions should fit the following: liver: total bilirubin ≤ 1.5 times of the normal maximum, alt and ast≤ 2.5 times of the normal maximum. (alt/ast≤ 5 times of the normal maximum for patients with infiltrative liver disease) kidney: serum creatinine ˂ 1.5 folds of the normal maximum; creatinine clearance rate ≥50ml/min (calculated by cockroft-gault10 formula) exclusion criteria: 1. history of hdaci treatment. 2. women during pregnancy or lactation. 3. patients with a second primary tumor ( this does not include non-melanoma skin cancer received systemic treatment, cured cervical carcinoma in situ of the uterus, or other tumors that have been cured with disease free survival˃ 5 years) 4. patients with central nervous system defects or mental disorders. 5. other diseases or contraindications: history of heart disease within 6 months prior to inclusion, including nyha iii-iv heart failure after treatment, coronary heart disease, angina pectoris, myocardial infarction, degree ii or iii atrioventricular block, severe arrhythmias that need medical treatment, uncontrolled hypertension; liver cirrhosis (child-pugh b or c); active infection that has not been controlled, and other conditions that may make the patient unable to complete the trial.

Keywords: cephalic and cervical adenocystic carcinoma chidamide
first trimester resistin levels in hg

Conditions: Hyperemesis Gravidarum - Severe; Resistin; Gestational Diabetes Mellitus (GDM)

Summary: this cross-sectional case-control study was conducted in tuzla state hospital obstetrics clinic in turkey. the study evaluated 400 pregnant women during their first trimester of pregnancy. many pregnant women (50-90%) experience nausea and vomiting during their first trimester; however, some patients have a disease called "hyperemesis gravidarum" (hg) characterized by very severe nausea and vomiting that may require hospitalization. resistin" is a peptide which is secreted primarily by human adipocytes and mononuclear cells. evidence suggests that resistin increases plasma glucose concentration, reduces glucose intake by adipocytes, and promotes insulin resistance. considering the hg effect on endocrinologic and metabolic complications, we hypothesized that resistin levels in maternal serum may change in the presence of hg; therefore, the aim of the present study was to evaluate these resistin levels during the first trimester and their correlation with hg severity.


Eligibility criteria:
inclusion criteria: those who applied in the first trimester and had a mid-trimester ogtt result exclusion criteria: 1) multifetal pregnancy, 2) fetal chromosomal or structural anomalies, 3) pregestational dm, 4) chronic hypertension or history of preeclampsia, 5) thyroid disease, 5) chronic kidney disease, 6) autoimmune disease, or 7) long-term use of aspirin or glucocorticoids 8) without ogtt results.

Keywords: first trimester maternal serum resistin hyperemesis gravidarum hg gdm
effects of yoga and relaxation on stress and quality of life

Conditions: Stress, Psychological

Summary: the aim of this study is to measure the effects of three stress reduction methods on patients with stress and stress associated complaints.


Eligibility criteria:
inclusion criteria: - stress with at least 4 of 10 points on the numeric analogue scale (nas) at least 1 month and at least 3 of the following 8 stress symptoms: sleep disorder, inappetence or increased appetite, shoulder neck tension/back pain, tension headache, concentration disorder, exhaustion, nervousness/irritability, stress-associated digestive problems exclusion criteria: * serious acute or chronic diseases * pregnancy or lactation * known serious mental illness * immobility or restriction for gymnastics exercises due to orthopaedic, neurological or other medical cause * participation in another study

Keywords: yoga meditation progressive muscle relaxation stress education
safety and efficacy of statins for chinese patients with dyslipidemia

Conditions: Dyslipidemias

Summary: this study is designed to verify the clinical efficacy and safety of different statins in dyslipidemia patients, and explore the effects on glycometabolic in patients with impaired glucose regulation.

study objective: 1. the main objective: to explore the effects of different statins lipid-lowering treatment on glucose metabolism in patients with impaired glucose regulation in a large sample of chinese population; 2. the secondary objective: to obtain real-world evidence of the clinical efficacy and safety of statins lipid-lowering therapy in chinese patients. study design: the study was an open-label, multi-center network register-based follow-up study. the total sample size: 10000 participants.

Eligibility criteria:
inclusion criteria: 1. patients with a clinical diagnosis of ascvd (acute coronary syndrome, stable coronary heart disease, postoperative revascularization, ischemic cardiomyopathy, ischemic stroke, transient ischemic attack, peripheral atherosclerotic disease). 2. ascvd overall risk assessment for high-risk groups: diabetic patients with ldl-c≥1.8mmol/l（70mg/dl）and age was equal or greater than 40 years old; 3. patients with hypertension, ldl-c \> 2.6mmol/l (100mg/dl) and combined with at least two risk factors. risk factors include smoking, low hdl-c (hdl-c\<1mmol/l, 40mg/dl), male aged over 45 years old or female aged over 55 years old; \*\*\* the above (1)-(3) are juxtapositions, patients can be included into the group if only they are satisfied with at least one of the inclusion criteria. exclusion criteria: 1. patients with any allergy to statins; 2. acs patients in acute stage； 3. patients with severe liver disease or biliary obstruction； 4. patients taking cyclosporine； 5. patients who have being treated with statins currently or in the past; 6. pregnant or lactating women and those women who planning to be pregnant; 7. immunodeficiency or immunocompromised patients; 8. patients with hypothyroidism (expect those patients whose thyroid function returned to normal level after drug therapy); 9. patients using systemic hormone drug; 10. researchers decided that the patients who was not suitable to participate in the study.

Keywords: dyslipidemia cardiovascular diseases hypertension ldl-c
radical fimbriectomy for young brca mutation carriers

Conditions: BRCA1 Mutation; BRCA2 Mutation; Hereditary Breast and Ovarian Cancer

Summary: some brca-mutated women are reluctant to undergo laparoscopic bilateral salpingo-oophorectomy. the goal of the bilateral laparoscopic radical fimbriectomy the investigators suggest, is to suppress the tubal source of possible dysplastic cells from which can stem this high grade tumor, while preserving a natural ovarian hormonal secretion.

most of ovarian carcinomas related to brca 1 or 2 mutations are of fallopian tube origin and especially from its distant part called the fimbria. these tubal, ovarian or primary peritoneal carcinomas are quite always of high grade serous type. they cannot be effectively screened due to the quickness of their evolution. in this context, a laparoscopic bilateral salpingo-oophorectomy (bso) is the recommended prophylactic procedure. some brca-mutated women are reluctant to undergo this procedure considering the numerous adverse effects on body and quality of life, especially when hormonal replacement is forbidden. this refusal makes them at risk of developing a serous pelvic carcinoma. the goal of the bilateral laparoscopic radical fimbriectomy the investigators suggest, is to suppress the tubal source of possible dysplastic cells from which can stem this high grade tumor, while preserving a natural ovarian hormonal secretion

Eligibility criteria:
inclusion criteria: * woman aged over 35 years * when project of childbearing is fulfilled * with a brca 1 or 2 mutation, or a family history of breast/ovarian cancer * unprepared to undergo bilateral annexectomy * with or without breast cancer * patient affiliated to health insurance * dated and signed informed consent exclusion criteria: * menopausal woman defined as : bilateral oophorectomy without hysterectomy and amenorrhea more than 12 months and/or fsh\> 20 ui/l history of hysterectomy and fsh\> 20 ui/l * pregnant or breastfeeding woman

Keywords: brca1 brca2 prophylactic surgery salpingectomy fimbriectomy
study on the surgical strategy of corneal endothelial protection for hard nuclear cataract patients

Conditions: Hard Nuclear Cataract; Phacoemulsification Cataract Surgery; Endothelial Cell Density Loss; Central Corneal Thickness

Summary: in this study, we compared two types of phacoemulsification commonly used in cataract surgery to evaluate their effect on the prognosis of patients with hard nuclei. this will provide a theoretical basis for selecting a more appropriate cataract surgery modality in practice in hard-nucleus patients.

in this study, we randomized patients into two groups. one group was the combined mode group in burst mode and the other group was the torsional ultrasound group in continuous mode. cumulative dissipated energy(cde) and ultrasound time(ust) were recorded during the procedure. changes in central cornea thickness(cct) and endothelial cell density(ecd) of the patients were recorded postoperatively during a 3-month follow-up. intraoperative and postoperative complications were also recorded. the above data were analyzed to compare the effect of both on postoperative corneal recovery in patients with hard nuclei.

Eligibility criteria:
inclusion criteria: * patients with age-related cataracts that were only classified by emery-little as nuclear hardness grade iii-v. * encompassed a minimum dilated pupil diameter of 7 mm or above, as well as a corneal endothelial cell count exceeding 1200/mm\^2. * corneal morphology is normal and clear * informed consent is required prior to enrollment exclusion criteria: * those with white cataracts, histories of eye surgery, and eye diseases such as corneal pathology, uveitis, fuchs\&#39; dystrophy, and glaucoma were excluded. * exclude those with comorbid ocular and systemic diseases that affect corneal endothelial cell function * exclude those with previous intraocular surgery

Keywords: hard nuclear cataract phacoemulisification mode ultrasound time cumulative dissipated energy
safety and immunogenicity of 20vpnc coadministered with siiv in adults ≥65 years of age

Conditions: Pneumococcal Disease

Summary: study of the safety and immunogenicity of 20vpnc and influenza vaccine administered at the same visit or separately


Eligibility criteria:
inclusion criteria: * male or female participants ≥65 years of age at the time of consent * adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease * adults who have no history of ever receiving a pneumococcal vaccine, or have a history of receiving a licensed pneumococcal vaccination ≥6 months prior to first study vaccination. exclusion criteria: * history of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) * previous vaccination with any investigational pneumococcal vaccine, or planned receipt of any licensed or investigational pneumococcal vaccine through study participation. * vaccination with any influenza or pneumococcal vaccine \<6 months before investigational product administration, or planned receipt of any licensed or investigational non-study influenza vaccine during study participation. -- serious chronic disorder, that in the investigator's opinion would make the participant inappropriate for entry into the study * other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results
comparing the spanish version of canreduce with or without psychological support and treatment as usual, reducing cannabis use.

Conditions: Cannabis Use Disorder

Summary: cannabis is the most widely used psychoactive substance around the world after alcohol and tobacco. although approximately one in ten users develop serious problems of dependency, only a small number attend outpatient addiction counseling centers. canreduce is an adherence-focused guidance enhanced web-based self-help program with promising results in german and other languages. it also reaches those users who hesitate to approach such treatment centers and help them to reduce their cannabis use. this study will test the effectiveness of the spanish version of the enhanced web-based self-help intervention with psychological support, an enhanced web-based self-help intervention (without psychological support) and a waiting list control in reducing cannabis use in problematic users.


Eligibility criteria:
inclusion criteria: * cannabis use of at least once a week 30 days prior to study entry * at least 18 years old * at least weekly internet access and a valid email address exclusion criteria: * participant reports current pharmacological psychiatric disease or history of psychosis, schizophrenia, bipolar type i disorder or significant current suicidal or homicidal thoughts * use of other pharmacological and psychosocial treatments for cannabis use disorders * inability to read or write in spanish

Keywords: mental health adherence, treatment cognitive behavioral therapy web-based self-help
liver transplant european study into the prevention of fungal infection

Conditions: Liver Transplantation; Mycoses

Summary: prevention of invasive fungal infection in high risk patients following liver transplant.

after receiving liver transplant, subjects will be randomized to one of the two treatment arms. study drugs will be administered for a period of 21 days, or until hospital discharge, whichever occurs first. additionally, mortality data will be collected at the long-term follow-up.

Eligibility criteria:
inclusion criteria: * undergoing orthotopic whole or split liver allograft transplantation * patients at 'high risk' of invasive fungal infection due to the presence of at least one of the following risk factors: * re-transplantation * acute liver failure * pre- or post-operative renal impairment (defined as creatinine clearance ≤40 ml/min) or need for renal replacement therapy * admission to intensive care unit (icu) for greater than 48 hours prior to liver transplant * re-operation (abdominal surgery) within 5 days of liver transplant * presence of choledocojejunostomy * perioperative colonization with fungi, defined as two or more positive clinical site surveillance cultures for candida spp., obtained within 96 hours before or after liver transplant * need for prolonged mechanical ventilation for greater than 48 hours following liver transplant * transfusion intraoperatively of 20 or more units of cellular blood products * female subject of childbearing potential must have a negative urine or serum pregnancy test prior to randomization and must agree to maintain effective birth control during the study exclusion criteria: * any systemic antifungal therapy (excluding fluconazole or oral nystatin for a maximum of 7 days) within 14 days prior to randomization * evidence of documented ('proven' or 'probable') or suspected ('possible') ifd (according to the eortc/msg criteria) * allergy, hypersensitivity, or any serious reaction to an echinocandin antifungal, or any of the study drugs or their excipients

Keywords: prophylaxis liver transplantation invasive fungal infection micafungin prevention mycoses
gdt-ppv protocol in thoracic surgery

Conditions: Thoracic Surgery; Fluid-therapy

Summary: peri-operative fluid-therapy is extremely important in thoracic surgery, because excessive administration of fluids during one-lung ventilation is correlated to an increasing risk of postoperative respiratory complications. therefore, current guidelines on peri-operative management of patients undergoing thoracic surgery suggest a conservative fluid management strategy, based on intra-operative fluid loss replacement and maintenance of euvolemia. nevertheless, intra-operative fluid loss estimation and consequently the correct infusion rate adoption are quite difficult to be addressed in clinical practice, and this often prevents the euvolemia maintenance in the peri-operative period. this limit claims the necessity to adopt new methods of fluid-therapy administration in thoracic surgery; among these the most promising is the "goal-directed therapy" (gdt). gdt protocols based on stroke volume variation (svv) or pulse pressure variation (ppv) monitoring have been adopted successfully in major and cardiac surgery but not yet in thoracic surgery. the aim of this randomized study is to evaluate the effects of a ppv-gdt fluid management protocol versus a conservative "zero-balance" protocol on intrapulmonary gas exchanges, in patients undergoing single-lung ventilation during thoracic surgery.

the intra-operative fluid-therapy (using lactated ringer) will be based on pulse pressure variation (ppv group) with a target ≤5.8% or on compensation (1:1) of urine output (zero balance group). in both groups an intraoperative background infusion of lactated ringer at 1-2 ml/kg/h will be administered.

Eligibility criteria:
inclusion criteria: * adult patients scheduled for video-assisted thoracic surgery (vats) lobectomy exclusion criteria: * patients who will not sign the informed consent * obesity (bmi \> 35 kg/m2) * cardiovascular disease (heart failure, arrhythmia) * osas requiring or not c-pap therapy * chronic alcoholism * intraoperative blod loss\> 1500 ml * one-lung ventilation duration\< 60 min

Keywords: pulse pressure variation zero balance single-lung ventilation
comparing treatment with melatonin to treatment with stimulants (methylphenidate) in children with attention deficit hyperactivity disorder and sleep difficulties

Conditions: Attention Deficit Hyperactivity Disorder; Sleep Onset Insomnia

Summary: the study hypothesis is that some children with attention-deficit-hyperactivity-disorder (adhd) who also have sleep onset difficulties will improve with melatonin treatment to an extent similar to that of stimulants treatment. in order to check this hypothesis children with a new adhd diagnosis who also have sleep difficulties will be treated with either melatonin or with stimulants (methylphenidate) for one month. the main outcome will be improvement of the adhd symptoms.


Eligibility criteria:
inclusion criteria: * children 6-18 years old with a new adhd diagnosis who are candidates for treatment with stimulants * also they suffer from sleep onset insomnia or difficult awakening exclusion criteria: * drug treatment for adhd or for sleep problems in the last 6 months * any other chronic medical treatment * sleep disorder requiring a different treatment * asthma in the last 2 years
vitamin d and zinc levels in patients undergoing ergometry test

Conditions: Atherosclerosis

Summary: low vitamin d levels were found to be associated with cardiovascular morbidity and mortality. low zinc levels are associated with an increased atherosclerotic burden. therefore we hypothesized that patients with pathological stress test would have low levels of vitamin d and zinc compared to patients with a normal stress test.

hypovitaminosis d is generally defined as 25(oh)d levels of \< 20ng/ml, while levels of 21-29ng/ml indicate insufficiency and those above 30ng/ml are regarded as sufficient. the rational behind the observations associating vitamin d deficiency with cvd is that on the one hand, hypovitaminosis d was found to be associated with traditional risk factors such as hypertension (htn),diabetes mellitus (dm),obesity, dyslipidemia and metabolic syndrome , on the other hand, experimental data demonstrated that vitamin d could affect cardiac muscle cells directly, control parathyroid (pth) hormone secretion, regulate the rennin- angiotensin- aldosterone system and the immune system, all of which could influence cardiovascular risk. epidemiological studies further support this association, demonstrating high prevalence of hypovitaminosis d among u.s. adults with cardiovascular disease (74%). an association between low vitamin d levels and increased myocardial infarction risk as well as total mortality has been also observed. low 25hydroxyvitamin d\[ 25(oh)d\] levels were also independently associated with all cause and cvd mortality among patients scheduled for coronary catheterization.

Eligibility criteria:
inclusion criteria: * over 18 years old * cct \> 60 ml/min * no ihd * no hyper/hypoparathyroidism * no active malignancy * not taking calcium, phosphate exclusion criteria: * under 18 years of age * not fulfilling inclusion criteria

Keywords: ergometry vitamin d zinc
supplementation trial of koko plus among hiv exposed children in accra

Conditions: HIV Infections; Nutrition Poor; Child Development

Summary: the overall aim of the research is to conduct a randomised controlled trial of kokoplus in young hiv exposed children attending hiv clinics in accra, ghana to test the effectiveness of kokoplus over a period of 6 months to improve nutritional status and child development in hiv exposed children 6-18 months of age in accra

the specific objectives are to accomplish the following 1. to test the effectiveness of kokoplus to improve the nutritional status of hiv exposed infants aged 6-18 months. 2. to measure and compare nutritional status in intervention and control arms by monitoring growth in terms of height and weight over the period of 6 months 3. to measure and compare micronutrient status of intervention and control arms by comparing baseline midline and endline measurements of hemoglobin levels. 4. to measure and compare morbidity rates of intervention and control arms. 5. to measure and compare rates of achievement of child development goals between intervention and control arms using a standardized tool, the caregiver reported early development instrument (credi). 6. to understand and record experiences relating to the use of kokoplus of mothers/caregivers in the intervention arm through focus group discussion

Eligibility criteria:
inclusion criteria: * mother-infant dyads; hiv positive mothers and children between 6 and 12 months of age attending antiretroviral (art) clinics and child hiv clinics. exclusion criteria: * mothers who decline to participate in the study children with severe acute malnutrition (mid-upper arm circumference \<115 mm or a weight-for-height/length \<-3 z-scores of the who growth standards). children on hospital admission children with diagnosed or apparent congenital conditions such as encephalitis, cleft palate, hole in heart, which negatively affect the child's ability to eat and/or growth.

Keywords: hiv-exposed nutrient status kokoplus